Please assess the completion status of the following clinical trial:

Trial Title: Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must sign voluntarily the informed consent from before any study test is conducted that is not part of routine patient care, with the knowledge that he/she can abandon the study at any time without this affecting his/her previous care.~* Aged between 18 and 70.~* Pathological diagnosis of non operable and/or metastatic soft tissue sarcoma.~* The following histological subtypes can be included:~  * Undifferentiated pleomorphic sarcoma (previously,malignant fibrous istiocytoma)~ * Leiomyosarcoma~ * Angiosarcoma~ * Liposarcoma~ * Synovial sarcoma~ * Fibrosarcoma~ * Hemangiopericytoma~ * Neurofibrosarcoma~ * Mixofibrosarcoma~ * Unclassified sarcoma~* Measurable disease, according to RECIST criteria~* Performance status 0-2 Eastern Cooperative Oncology Group(ECOG).~* Adequate bone marrow function (hemoglobin \> 10 g/dL, leukocytes ≥ 3.000/mm3, neutrophils ≥1.500/mm3, platelets ≥ 100.000/mm3). Patients with plasma creatinine ≤ 1,6 mg/dL, transaminases ≤2.5 times the upper limit of normal (ULN), total bilirubin ≤ upper limit of normal (ULN), CPK ≤ 2.5 times upper limit of normal (ULN), alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN) are acceptable. If the increase of alkaline phosphatase is \> 2.5 times the upper limit of normal (ULN), then the alkaline phosphatase liver fraction and/or 5' nucleotidase and/or GGT must be ≤ upper limit of normal (ULN).~* Men or women of child bearing potential should be using an effective method of contraception before entry into the study and throughout the same and for 6 months after ending the study. Women of childbearing potential must have a negative urine pregnancy test before study entry.~* Normal cardiac function with a Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram or Multiple Uptake Gated Acquisition Scan (MUGA).~Exclusion Criteria:~* Previous chemotherapy treatment.~* Previous radiotherapy involving the only localization(s) of measurable tumoral disease.~* Performance status\> 2 Eastern Cooperative Oncology Group(ECOG).~* Central Nervous System (CNS) metastases.~* Plasma bilirubin \> upper limit of normal(ULN).~* Creatinine \> 1.6 mg/dL.~* History of other neoplastic disease with the exception of basalioma or in situ cervical cancer adequately treated.~* Significant cardiovascular disease (for example, dyspnea \> 2 NYHA)~* Significant systemic diseases grade 3 or higher on the NCI-CTC version 3.0 scale, that limit patient availability, or according to investigator judgment may contribute significantly to treatment toxicity.~* Uncontrolled bacterial, mycotic or viral infections.~* Women who are pregnant or breast-feeding~* Psychological, familial, social or geographic circumstances that limit the patient's ability to comply with the protocol or informed consent.~* Patients participating in another clinical trial or receiving any other investigational product.~* Patients who had participated in another clinical trial and/or had received any other investigational product in the last 30 days prior to inclusion.~* The following histologic subtypes are excluded:~  * Rhabdomyosarcoma~ * Ewing's family of tumors~ * Desmoplastic small round cell tumor~ * Clear cell sarcoma~ * Alveolar sarcoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous
- Arm B (Type: EXPERIMENTAL): Trabectedin Presentation: vials with trabectedin 1 mg and sucrose 400 mg. Pharmaceutical form: A white or whitish lyophilized powder as concentrate for solution for injection.~Route of administration: for intravenous use after reconstitution and further dilution.~Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy